Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06792695 · ClinicalTrials.gov registry record · Phase 2
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
A Phase 2 study of Metastatic Colorectal Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT06792695: Recruiting Phase 2 study of Metastatic Colorectal Cancer, sponsored by AstraZeneca.
NCT06792695 is a Phase 2 study of Metastatic Colorectal Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 120 participants, below the 183-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06792695, a Phase 2 study of Metastatic Colorectal Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
Primary Outcome
PFS is defined as the time from randomization until progression per Response Evaluation Criteria in Solid Tumours, Version 1.1 (RECIST 1.1) or death due to any cause.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Volrustomig
- DRUG FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)
Study Locations (20)
Other
- Research Site - East Melbourne
- Research Site - Wollongong
- Research Site - Woodville South
Ontario
- Research Site - Barrie
- Research Site - Toronto
Arizona
- Research Site - Scottsdale
California
- Research Site - Los Angeles
District of Columbia
- Research Site - Washington D.C.
Illinois
- Research Site - Chicago
Maryland
- Research Site - Baltimore
Massachusetts
- Research Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-03-12 |
| Est. Completion | 2028-06-07 |
| Phase | Phase 2 |
What NCT06792695 shows while recruiting
NCT06792695 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 183-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT06792695 names 20 study sites across 17 states, led by Other, Ontario, Arizona.
Frequently Asked Questions
What is clinical trial NCT06792695 about?
NCT06792695 is a clinical study titled "A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer". The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
What is the current status of trial NCT06792695?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-03-12. Estimated completion is 2028-06-07.
What conditions does trial NCT06792695 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT06792695?
The interventions under investigation include: Bevacizumab (DRUG), Volrustomig (DRUG), FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan) (DRUG).
Who is sponsoring clinical trial NCT06792695?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06792695 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06792695's enrollment target sits among peer trials
120 18th of 45 higher than 27 of 45 other Metastatic Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
RECRUITING · Phase 2
-
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
RECRUITING · Phase 2
-
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI